Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Assets (2019 - 2025)

BridgeBio Pharma's Assets history spans 7 years, with the latest figure at $936.0 million for Q4 2025.

  • For Q4 2025, Assets rose 1.82% year-over-year to $936.0 million; the TTM value through Dec 2025 reached $936.0 million, up 1.82%, while the annual FY2025 figure was $936.0 million, 1.82% up from the prior year.
  • Assets for Q4 2025 was $936.0 million at BridgeBio Pharma, down from $998.2 million in the prior quarter.
  • Across five years, Assets topped out at $1.1 billion in Q1 2021 and bottomed at $503.7 million in Q2 2023.
  • The 5-year median for Assets is $831.2 million (2022), against an average of $822.6 million.
  • The largest annual shift saw Assets tumbled 41.59% in 2023 before it surged 68.26% in 2024.
  • A 5-year view of Assets shows it stood at $1.0 billion in 2021, then tumbled by 38.48% to $623.0 million in 2022, then fell by 12.3% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then grew by 1.82% to $936.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Assets are $936.0 million (Q4 2025), $998.2 million (Q3 2025), and $1.1 billion (Q2 2025).